Copies of the full analyst report from Maxim and H.C. Wainwright, respectively, can be obtained upon request directly from Maxim and H.C. Wainwright.
“We are thrilled to receive these recommendations from such esteemed analysts and truly believe that both reports echo our internal beliefs about our groundbreaking technology,” said
Disclaimers
The research analysts primarily responsible for the preparation of the Maxim and the H.C. Wainwright research reports have received compensation based upon various factors, including the respective firm’s total revenues, a portion of which is generated by investment banking activities. Maxim makes a market in
Although BWV has paid the above compensation to the analysts, BWV is not responsible for the content, accuracy or timelines contained in an analyst’s report and the fee was not dependent on the opinion provided.
All reports on BWV prepared by analysts represent the views of such analysts and are not necessarily those of BWV. BWV is not responsible for the content, accuracy or timelines provided by analysts. BWV does not expressly or by implication warrant or assume any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, assumption, data, forecast, price target, estimate or projection contained in the reports or industry notes provided by analysts, and the dissemination of such reports or industry notes does not necessarily constitute or imply BWV’s endorsement or recommendation.
About
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on BWV’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the development of BWV’s vaccine candidates; the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any vaccine under development, there are significant risks in the development, regulatory approval and commercialization of new products. BWV does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in BWV’s Registration Statement on Form S-1, filed with the
Media Contact Information:
Blue Water Media Relations
Telephone: (646) 942-5591
Email: Nic.Johnson@russopartnersllc.com
Investor Contact Information:
Blue Water Investor Relations
Email: investors@bluewatervaccines.com
Source:
2022 GlobeNewswire, Inc., source